Ionis Pharmaceuticals, Inc. IONS 深 沪
交易中 10-06 10:23:24 美东时间
43.625
+0.125
+0.29%
华盛通- 最 高64.19
- 今 开43.82
- 成交量 25.92万股
- 最 低 42.63
- 昨 收 43.50
- 总市值 619.48万
- 52周最高 86.74
- 市盈率 静 --
- 换手率 182.53%
- 52周最低 42.63
- 委 比 -15.79%
- 总股本 0.00亿
- 历史最高 86.74
- 量 比 1.13
- 振 幅 49.56%
- 历史最低 1.10
- 每 手 1
- 风险率 10.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ionis to Seek Expedited FDA Review for ALS Drug
Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.
09-23 00:11
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
09-22 22:40
Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. Novartis obtained global rights to develop, manufacture and commercialize pelacarsen under a license and collaboration agreement with the company.
Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis afte...
09-05 04:41
Wolfe Research Downgrades Ionis Pharmaceuticals to Peer Perform
Wolfe Research analyst Andy Chen downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Peer Perform.
07-16 18:40
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $893.928M Est
Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $893.928 million estimate.
07-10 18:14
Ionis, AstraZeneca Pivotal Heart Disease Drug Flunks
Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained favorable.
07-09 20:09
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing deal for zilganersen
06-26 00:25
GSK Targets China's Hepatitis B Market Through New Deal
GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while launching its final buyback tranche.
05-12 00:03
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts
In the latest quarter, 6 analysts provided ratings for Ionis Pharmaceuticals (N...
02-07 05:00
What Does the Market Think About Ionis Pharmaceuticals Inc?
Ionis Pharmaceuticals Inc's (NYSE:IONS) short interest as a percent of float ha...
2025-12-04 23:01
